(Q38942767)

7 September 2017

1 reference

title

Low-grade serous ovarian cancer: A review (English)

1 reference

low-grade serous carcinoma

7 September 2017

1 reference

0 references

6

Steven A Narod

1 reference

7 September 2017

Anis Kaldawy

1

1 reference

7 September 2017

Yakir Segev

2

1 reference

7 September 2017

Ofer Lavie

3

1 reference

7 September 2017

Ron Auslender

4

1 reference

7 September 2017

Victoria Sopik

5

1 reference

7 September 2017

language of work or name

English

0 references

publication date

28 August 2016

1 reference

7 September 2017

1 reference

7 September 2017

volume

143

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

433-438

1 reference

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Gene expression patterns in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

The heterogeneity of epithelial ovarian cancer: getting it right

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Histopathologic grading of ovarian carcinoma: a review and proposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Low-grade serous carcinoma: new concepts and emerging therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Epidemiology of low-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Diagnosis, treatment, and follow-up of borderline ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Serous ovarian tumors of low malignant potential with peritoneal implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Survey of clinical behavior of patients with borderline epithelial tumors of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Inherited Mutations in Women With Ovarian Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

The molecular pathology of ovarian serous borderline tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Systemic therapy for ovarian cancer: current status and new treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Low-grade serous ovarian cancer: a unique disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Recurrent micropapillary serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Bevacizumab and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.08.320

10.1016/J.YGYNO.2016.08.320

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference